Advances in genetic testing and targeted therapy now mean patients can live longer. However, underused genetic testing and its inconsistent application impede outcomes and increase costs. Integrating genetic testing into treatment planning is key to intelligent oncology drug management.
Customizing cancer treatment with genetic testing means enhanced results and minimized side effects. Yet, many miss out on appropriate testing, and those tested often don’t have results to influence treatment.
Studies show that next-gen sequencing over single-gene testing for certain types of lung cancer can significantly reduce costs1. Broader testing initially costs more but leads to long-term savings2. An optimal oncology drug management program could reduce the time between diagnosis and the start of treatment from 40-60 days to just 10-15 days.
Streamlining genetic testing authorization, establishing foolproof testing protocols, and matching test results with best-fit therapies can revolutionize oncology management. Collaborating with third-party organizations specializing in lab value management can add expertise and efficiency to treatment processes.
Research has established that enhanced genetic testing management can lead to substantial cost savings and improved patient outcomes3. It’s time to action these insights and pave the way for a brighter future in cancer care by integrating personalized oncology drug management.
Ready to optimize your health plan with advanced genetic testing and personalized treatment strategies? Partner with us – the trailblazers in lab value management. Read about revolutionizing cancer treatment with better oncology drug management in The Cancer Letter by visiting Matt Ingram – The Cancer Letter.
References
1A 2023 study in JCO Precision Oncology highlighted the economic benefits of next-generation sequencing (NGS) over single-gene testing (SGT) for non-small cell lung cancer (NSCLC). Each 10% increase in NGS testing could save $75 per life year gained (LYG).
2Though initially more expensive, broad panel testing can lead to substantial savings in the long run. For instance, a 2020 study found that broad panel testing could save $8,500 per member per month (PMPM) compared to sequential testing.
3Research shows that better management of genetic testing in NSCLC can lead to significant cost savings and improved outcomes. A study found that 44% of NSCLC patients with positive biomarkers were not on recommended therapy, highlighting the need for improved management.